Maximum quantity allowed is 999
Please select the quantity
Boron-Containing Building Blocks for Medicinal Research: Benzoxaboroles
Boronic acids are recognized as useful scaffolds for pharmaceutical compounds, due to their unique property to form a reversible covalent bond at the boron center with various nucleophilic functional groups. Particularly, benzoxaboroles have gathered much interest as a boron-containing scaffold for bioactive compounds such as tavaborole (leucyl-tRNA synthetase inhibitor) and crisaborole (PDE4 inhibitor), with unique mechanisms of action.1,2) We offer a wide range of benzoxaboroles with various functional groups on each benzene ring useful for further derivatizations like 1, 2, 3, 4, 5, 6 and 7,3,4) and we also can provide custom synthesis of derivatives including bulk synthesis.
Related Products
- D6273
- 5-Amino-2,1-benzoxaborol-1(3H)-ol
- A2559
- 6-Amino-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
- D6277
- 2,1-Benzoxaborole-1,5(3H)-diol
- D6275
- Benzo[c][1,2]oxaborole-1,6(3H)-diol
- D6272
- 1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-5-carboxylic Acid
- D6270
- 1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxylic Acid
- D6271
- 1-Hydroxy-1,3-dihydro-2,1-benzoxaborole-7-carboxylic Acid
- H1280
- 2-(Hydroxymethyl)phenylboronic Acid Cyclic Monoester
- T3775
- Tavaborole
References
- 1) Recent developments in the medicinal chemistry of single boron atom-containing compounds
- 2) The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry
- 3) Design, Synthesis, and Structure−Activity Relationship of Trypanosoma brucei Leucyl-tRNA Synthetase Inhibitors as Antitrypanosomal Agents
- 4) Discovery of Novel Benzoxaborole-Based Potent Antitrypanosomal Agents